Showing results (71-80 of 155) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Journal for Immunotherapy of Cancer|January 30, 2019
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)Jean-Pascal Machiels, Ramon Salazar, Sylvie Rottey, et al.
British Journal of Cancer|October 6, 2020
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumoursDebbie G J Robbrecht, Juanita Lopez, Emiliano Calvo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2016
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid TumorsEmiliano Calvo, Jean-Charles Soria, Wen Wee Ma, et al.
Investigational New Drugs|April 24, 2015
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancerAnalia Azaro, Jordi Rodon, Antonio Calles, et al.
American Journal of Clinical Oncology|June 1, 2004
Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Emiliano Calvo, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resectionRocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, et al.
Oncology|November 29, 2002
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancerJavier Cortes, Javier Rodriguez, Jose Manuel Aramendia, et al.
Pageof 16